# EDGAR Filing Document

**Accession Number:** 0001779092
**File Stem:** 0001209191-23-007355
**Filing Date:** 2023-2
**Character Count:** 7936
**Document Hash:** 9791d077da9fbb8900d09017e884aab7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-007355.hdr.sgml**: 20230206

**ACCESSION NUMBER**: 0001209191-23-007355

**CONFORMED SUBMISSION TYPE**: 4/A

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20220611

**FILED AS OF DATE**: 20230206

**DATE AS OF CHANGE**: 20230206

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Duraibabu Prathyusha
- **CENTRAL INDEX KEY:** 0001779092

**FILING VALUES:**
- **FORM TYPE:** 4/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30171
- **FILM NUMBER:** 23592018

**MAIL ADDRESS:**
- **STREET 1:** C/O SANGAMO THERAPEUTICS, INC.
- **STREET 2:** 501 CANAL BLVD.
- **CITY:** RICHMOND
- **STATE:** CA
- **ZIP:** 94804
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SANGAMO THERAPEUTICS, INC
- **CENTRAL INDEX KEY:** 0001001233
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 680359556
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 7000 MARINA BLVD
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005
- **BUSINESS PHONE:** 5109706000

**MAIL ADDRESS:**
- **STREET 1:** 7000 MARINA BLVD
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SANGAMO BIOSCIENCES INC
- **DATE OF NAME CHANGE:** 20000208

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4/A

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Duraibabu Prathyusha<br><sub>(Last) (First) (Middle)</sub><br>C/O SANGAMO THERAPEUTICS, INC.<br>7000 MARINA BLVD.<br><sub>(Street)</sub><br>BRISBANE, CA 94005<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2022-06-11 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_SVP, Chief Financial Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>SANGAMO THERAPEUTICS, INC [ SGMO ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2022-06-11 |  | F |  | 864<sup>(1)</sup> | D | $3.76 | 86595<sup>(2)(3)(4)</sup> | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on June 11, 2022 which were surrendered by the Reporting Person to the Issuer solely for mandatory tax withholding purposes using the Issuer's closing stock price on June 10, 2022 of $3.76/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP").  This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

(2) Includes: (a) 1,658 shares resulting from the June 11, 2022 annual vesting installment of the Reporting Person's June 11, 2021 RSU grant and 5,000 shares subject to such grant that will vest in two remaining annual installments of 2,500 shares on each of June 11, 2023 and 2024, (b) 5,501 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in one final annual installment on February 25, 2023, (c) 9,167 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 4,583 shares and 4,584 shares on February 25, 2023 and 2024, respectively, (continued in footnote 3)

(3) (d) 41,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, and (e) 1,000 shares subject to the Reporting Person's March 25, 2020 RSU grant that will vest in one final annual installment on March 25, 2023. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

(4) Includes 687 shares acquired on May 31, 2022 under the Issuer's 2020 Employee Stock Purchase Plan.

**Remarks:**
This Form 4/A is being filed solely to correct the number of shares reported as disposed of by the Reporting Person in Item 4 of Table I, which was erroneously reported to be 842 shares.

**Signature:** Prathyusha Duraibabu, by /s/ Ron A. Metzger, Attorney-in-Fact  
**Date:** 2023-02-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**